Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study

Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study

Abstract Background Effective treatment of late antibody-mediated rejection (late AMR) is still an unmet medical need. Clearing donor-specific antibody (DSA) and preventing its rebound is the ideal goal of treatment. Methods We have summarized the clinical data from seven patients with late or chron...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhiliang Guo, Rula Sa, Daqiang Zhao, Songxia Li, Hui Guo, Lan Zhu, Gang Chen
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Nephrology
Subjects:
Antibody-mediated rejection
Donor-specific antibody
Daratumumab
Kidney transplantation
Tocilizumab
Online Access:https://doi.org/10.1186/s12882-025-03951-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items